Nextech Invest appeared to be the VC, which was created in 1998. The fund was located in Europe if to be more exact in Switzerland. The main department of described VC is located in the Zu00fcrich.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Nextech Invest, startups are often financed by Third Rock Ventures, OrbiMed, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Casdin Capital, The Column Group. In the next rounds fund is usually obtained by Future Capital, Wellington Management, The Column Group.
Besides them, we counted 4 critical employees of this fund in our database.
The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Vividion Therapeutics, TetraLogic Pharmaceuticals, Kura Oncology Among the most successful fund investment fields, there are Clinical Trials, Medical Device. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
Comparing to the other companies, this Nextech Invest performs on 35 percentage points more the average number of lead investments. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2015. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | 23 Oct 2024 | Vancouver, British Columbia, Canada | |||
Idrx | $120M | 07 Aug 2024 | - | ||
Scorpion Therapeutics | $150M | 16 Jul 2024 | Boston, Massachusetts, United States | ||
Delphia Therapeutics | $67M | 02 May 2024 | - | ||
Alterome Therapeutics | $132M | 03 Apr 2024 | San Diego, California, United States | ||
Tubulis | $151M | 14 Mar 2024 | Munich, Bavaria, Germany | ||
Esker Therapeutics | $259M | 06 Mar 2024 | - | ||
ProfoundBio | $112M | 13 Feb 2024 | Suzhou, Jiangsu, China | ||
Synnovation Therapeutics | $102M | 14 Dec 2023 | Wilmington, Delaware, United States |
– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
– Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.
– Atavistik Bio, a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced that the closing of a $60 million Series A financing round.
– The financing was led by The Column Group and joined by Lux Capital, and Nextech Invest.
– The new financing will support development of Atavistik’s drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically regulated by metabolites.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | 23 Oct 2024 | Vancouver, British Columbia, Canada | |||
Idrx | $120M | 07 Aug 2024 | - | ||
Scorpion Therapeutics | $150M | 16 Jul 2024 | Boston, Massachusetts, United States | ||
Delphia Therapeutics | $67M | 02 May 2024 | - | ||
Alterome Therapeutics | $132M | 03 Apr 2024 | San Diego, California, United States | ||
Tubulis | $151M | 14 Mar 2024 | Munich, Bavaria, Germany | ||
Esker Therapeutics | $259M | 06 Mar 2024 | - | ||
ProfoundBio | $112M | 13 Feb 2024 | Suzhou, Jiangsu, China | ||
Synnovation Therapeutics | $102M | 14 Dec 2023 | Wilmington, Delaware, United States |
